Oxford Bioscience Partners - Boston, MA
|
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. Experienced partners, who bring together deep domain knowledge in life sciences, have established a proven track record of identifying, validating and backing emerging trends and technologies. While willing to consider an investment in a company at almost any stage, OBP brings unique value and expertise to early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide, and has successfully leveraged the extensive research, operating, and financial expertise and experience of its team of investment professionals.
Oxford's team of investment professionals has a history of backing leading life science companies, including: SIRNA (acquired by Merck); SOLEXA (acquired by Illumina); ALANTOS (acquired by Amgen); TRUBION (NASDAQ: TRBN); HYPNION (acquired by Eli Lilly); HUMAN GENOME SCIENCES (NASDAQ: HGSI); POWDERMED (acquired by Pfizer); ACADIA (NASDAQ; ACAD); PVT (acquired by Edwards); EXELIXIS (NASDAQ: EXEL); SOSEI (Nikkei: 4565); COHESIVE (acquired by Thermo Fisher); IMPELLA (acquired by Abiomed); STRATAGENE (acquired by Agilent); SANTHERA (SWX:SANN); EXONHIT (EURONEXT: ALEHT); INVERNESS MEDICAL (NYSE: IMA)
|
| |
|
|
 |
|
|
 |
|
October 21, 2009
Advisory Board Meetings
@ Oxford Bioscience Partners
222 Berkeley Street, Suite 1650
Boston, MA 02116
October 22, 2009
Annual Limited Partners Meeting
@ Four Seasons Hotel
200 Boylston Street
Boston, MA 02116
February 2, 2009
New England VCs Well Down Midas List—Oxford’s Fambrough Leads Pack
September 19, 2007
Oxford Bioscience Partners Promotes Dr. Douglas Fambrough to General Partner
July 6, 2007
Oxford Bioscience Keeps Successes on the QT
March 11, 2010
AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering --
moreMarch 3, 2010
ExonHit reports out-licensing of EHT/AGN 0001 --
moreMarch 3, 2010
Molecular Biometrics Announces Launch of Viametrics-E™ --
moreMarch 2, 2010
Abbott and Enanta Announce Advancement of Hepatitis C Collaboration-- Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals --
moreMarch 2, 2010
Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program --
moreFebruary 23, 2010
ExonHit announces the inclusion of proprietary lead compounds into Allergan collaboration --
moreFebruary 11, 2010
ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer’s disease --
moreFebruary 9, 2010
Astex Executive Receives the AstraZeneca Business Development Professional of the Year 2009 Award --
more
|
|
|
|